Summary of CABANA-HF Cooperative Agreement Award

IHC Health Services Inc., doing business as Intermountain Healthcare, received a $1.29M cooperative agreement from the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 10, 2026, with an ultimate completion date of June 30, 2027. The award funds Intermountain Healthcare's participation in the CABANA-HF (Catheter Ablation Versus Antiarrhythmic and Heart Failure Drug Therapy in Preserved Ejection Fraction Heart Failure) clinical trial, a multi-center, randomized controlled study designed to evaluate whether percutaneous left atrial catheter ablation combined with guideline-directed medical therapy provides superior outcomes compared to medical therapy alone for patients with heart failure with preserved ejection fraction and atrial fibrillation.

As a clinical research site, Intermountain Healthcare delivers patient recruitment, protocol implementation, institutional review board coordination, clinical data collection, and electronic health record data extraction and harmonization services to support the trial's 5-year duration (3 years recruitment, 2 years follow-up) and enrollment of 1,552 patients across multiple centers. The trial's primary endpoints include cardiovascular mortality or worsening heart failure, with secondary endpoints encompassing all-cause mortality, quality of life assessments, and cost-effectiveness analyses. An independent clinical events committee will adjudicate primary and major secondary clinical events. Intermountain Healthcare's role aligns with its established footprint as a clinical research partner within multi-institutional consortia sponsored by the National Heart, Lung, and Blood Institute.